Valuation: Sera Prognostics, Inc.

Market Cap 78.71M 68.88M 63.48M 58.84M 112M 7.47B 113M 761M 296M 3.69B 295M 289M 12.74B P/E 2026 *
-3.07x
P/E 2027 * -3.59x
Enterprise Value 78.71M 68.88M 63.48M 58.84M 112M 7.47B 113M 761M 296M 3.69B 295M 289M 12.74B EV / Sales 2026 *
217x
EV / Sales 2027 * 29.4x
Free-Float
86.31%
Yield 2026 *
-
Yield 2027 * -
1 day-3.83%
1 week+10.44%
Current month+10.44%
1 month-12.23%
3 months-6.94%
6 months-39.09%
Current year-31.86%
1 week 1.79
Extreme 1.7901
2.12
1 month 1.72
Extreme 1.725
2.24
Current year 1.56
Extreme 1.56
3.85
1 year 1.56
Extreme 1.56
3.95
3 years 1.37
Extreme 1.37
12.36
5 years 1.1
Extreme 1.1
15.5
10 years 1.1
Extreme 1.1
15.5
Manager TitleAgeSince
Chief Executive Officer 52 31/05/2023
Director of Finance/CFO 39 06/06/2023
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Director/Board Member 68 28/11/2021
Director/Board Member 63 30/06/2026
Chairman 74 19/04/2011
Date Insider Type Main position Quantity % Market Cap.
06-10Sell

Chief Technology Officer

-362 0.0009%
06-10Sell

Chief Financial Officer

-2,037 0.0053%
06-10Sell

Executive/Senior Manager

-4,739 0.0124%
Change 5-day change 1-year change 3-year change Capi.($)
-3.83%+10.44%-16.94%-38.34% 78.71M
-0.87%+0.53%+13.38%+15.41% 23.34B
-0.93%-13.20%+20.96% - 17.82B
-2.46%+6.30%+93.32%+55.90% 3.72B
-2.24%+1.01%+19.42%-26.10% 3.44B
-12.57%-8.47%+198.02%+208.21% 2.3B
-0.39%-0.80%+174.54%+283.68% 1.94B
-3.19%+4.12%-35.25%-45.51% 1.79B
-3.30%-2.22%-30.12% - 1.76B
-1.76%+2.79%+5.68%+10.63% 1.67B
Average -3.15%-3.83%+44.30%+57.98% 5.79B
Weighted average by Cap. -1.69%-5.11%+30.88%+37.66%

Financials

2026 *2027 *
Net sales 362K 317K 292K 271K 514K 34.4M 523K 3.51M 1.36M 16.98M 1.36M 1.33M 58.69M 2.68M 2.34M 2.16M 2M 3.8M 254M 3.86M 25.87M 10.06M 125M 10.04M 9.83M 433M
Net income -33.26M -29.11M -26.82M -24.86M -47.2M -3.16B -47.96M -322M -125M -1.56B -125M -122M -5.38B -29.98M -26.23M -24.18M -22.41M -42.54M -2.85B -43.23M -290M -113M -1.4B -113M -110M -4.85B
Net Debt - -
Logo Sera Prognostics, Inc.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Employees
72
Date Price Change Volume
07/07/26 US$2.010 -3.83% 7,833
06/07/26 US$2.090 +4.50% 59,989
02/07/26 US$2.000 -1.48% 25,951
01/07/26 US$2.030 +11.54% 24,333
30/06/26 US$1.820 +0.55% 39,882
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.010USD
Average target price
5.500USD
Spread / Average Target
+173.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SERA Stock